Core Insights - BioLife Solutions, a provider of bioproduction tools for cell and gene therapy, reported a significant insider sale by its CFO, Troy Wichterman, who sold 30,000 shares for approximately $771,600 amid a modestly declining share price [2][9]. Transaction Summary - The CFO sold 30,000 shares at a weighted average price of $25.72, resulting in a transaction value of about $771,600 [3]. - Post-transaction, Wichterman holds 152,769 shares, which is approximately 60.5% of his holdings at the start of the reporting period [4]. - This sale represents 16.4% of his direct ownership [4]. Company Overview - As of December 4, 2025, BioLife Solutions has a market capitalization of $1.19 billion and reported a revenue of $100.1 million for the trailing twelve months [5]. - The company's stock price has decreased by 2.1% over the past year [5]. Recent Performance - In early November, BioLife Solutions reported a 31.2% increase in revenue to $28.1 million for the third quarter, with the operating loss narrowing from $418,000 to $89,000 [10]. - Despite the revenue growth, the stock has declined by 5.5% over the past year, underperforming compared to the S&P 500 and Nasdaq Composite, which returned 15.6% and 20.2%, respectively [10]. Company Profile - BioLife Solutions specializes in bioproduction tools and services for the cell and gene therapy sector, utilizing proprietary preservation and logistics technologies [8]. - The company serves biotechnology and pharmaceutical companies, academic research institutions, and commercial manufacturers of biologic-based therapies across various international markets [14].